May 5, 2018, at 6:15 am ET
Underutilized to Ubiquitous: Genetic Testing for Breast Cancer
Genetic testing for breast cancer risk is finally becoming commonplace and routine in the clinic. But in addition to the tests ordered, physicians are now given genetic information from new sources, such as direct-to-consumer (DTC) testing, whole genome sequencing of people, whole exome sequencing of tumors, and others. Join Dr. Kevin Hughes, Co-Director, MGH Avon Comprehensive Breast Evaluation Center, Associate Professor, Surgery, Harvard Medical School, and Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic as he discusses how to manage the results of traditional genetic testing as well as the results of genetic tests physicians did not order.
For more information, contact Rhea Daugherty at firstname.lastname@example.org.
NOTE: This satellite symposium is supported by 23andMe, Inc. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.
Dr. Kevin Hughes
Co-Director, MGH Avon Comprehensive Breast Evaluation Center
Associate Professor, Surgery, Harvard Medical School
Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic